179 related articles for article (PubMed ID: 38295285)
1. Clinical features of neurotoxicity after CD19 CAR T-cell therapy in mantle cell lymphoma.
Nie EH; Su YJ; Baird JH; Agarwal N; Bharadwaj S; Weng WK; Smith M; Dahiya S; Han MH; Dunn JE; Kipp LB; Miklos DB; Scott BJ; Frank MJ
Blood Adv; 2024 Mar; 8(6):1474-1486. PubMed ID: 38295285
[TBL] [Abstract][Full Text] [Related]
2. CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim results.
Park JH; Nath K; Devlin SM; Sauter CS; Palomba ML; Shah G; Dahi P; Lin RJ; Scordo M; Perales MA; Shouval R; Tomas AA; Cathcart E; Mead E; Santomasso B; Holodny A; Brentjens RJ; Riviere I; Sadelain M
Nat Med; 2023 Jul; 29(7):1710-1717. PubMed ID: 37400640
[TBL] [Abstract][Full Text] [Related]
3. Imaging-based Toxicity and Response Pattern Assessment Following CAR T-Cell Therapy.
Smith DA; Kikano E; Tirumani SH; de Lima M; Caimi P; Ramaiya NH
Radiology; 2022 Feb; 302(2):438-445. PubMed ID: 34751616
[TBL] [Abstract][Full Text] [Related]
4. Multifocal demyelinating leukoencephalopathy and oligodendroglial lineage cell loss with immune effector cell-associated neurotoxicity syndrome (ICANS) following CD19 CAR T-cell therapy for mantle cell lymphoma.
Nie EH; Ahmadian SS; Bharadwaj SN; Acosta-Alvarez L; Threlkeld ZD; Frank MJ; Miklos DB; Monje M; Scott BJ; Vogel H
J Neuropathol Exp Neurol; 2023 Jan; 82(2):160-168. PubMed ID: 36592076
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Toxicity of CD19 Chimeric Antigen Receptor T Cell Therapy for Lymphoma in Solid Organ Transplant Recipients: A Systematic Review and Meta-Analysis.
Yamshon S; Gribbin C; Chen Z; Demetres M; Pasciolla M; Alhomoud M; Martin P; Shore T
Transplant Cell Ther; 2024 Jan; 30(1):73.e1-73.e12. PubMed ID: 37279856
[TBL] [Abstract][Full Text] [Related]
6. Use of long-term corticosteroids in patients treated with CAR T-cell therapy.
Hashmi H; McGann M; Greenwell BI
J Oncol Pharm Pract; 2023 Mar; 29(2):473-476. PubMed ID: 35635259
[TBL] [Abstract][Full Text] [Related]
7. Clinical Presentation, Risk Factors, and Outcomes of Immune Effector Cell-Associated Neurotoxicity Syndrome Following Chimeric Antigen Receptor T Cell Therapy: A Systematic Review.
Grant SJ; Grimshaw AA; Silberstein J; Murdaugh D; Wildes TM; Rosko AE; Giri S
Transplant Cell Ther; 2022 Jun; 28(6):294-302. PubMed ID: 35288347
[TBL] [Abstract][Full Text] [Related]
8. Prophylactic Tocilizumab Prior to Anti-CD19 CAR-T Cell Therapy for Non-Hodgkin Lymphoma.
Caimi PF; Pacheco Sanchez G; Sharma A; Otegbeye F; Ahmed N; Rojas P; Patel S; Kleinsorge Block S; Schiavone J; Zamborsky K; Boughan K; Hillian A; Reese-Koc J; Maschan M; Dropulic B; Sekaly RP; de Lima M
Front Immunol; 2021; 12():745320. PubMed ID: 34712233
[TBL] [Abstract][Full Text] [Related]
9. Host metabolome predicts the severity and onset of acute toxicities induced by CAR T-cell therapy.
Jalota A; Hershberger CE; Patel MS; Mian A; Faruqi A; Khademi G; Rotroff DM; Hill BT; Gupta N
Blood Adv; 2023 Sep; 7(17):4690-4700. PubMed ID: 36399526
[TBL] [Abstract][Full Text] [Related]
10. Severe persistent neurotoxicity associated with CAR T therapy in children.
Andrew EC; Hughes D; Gilsenan M; Mignone C; Khaw SL; Wang SS
Br J Haematol; 2023 Nov; 203(4):651-655. PubMed ID: 37528536
[TBL] [Abstract][Full Text] [Related]
11. Brexucabtagene autoleucel: a breakthrough in the treatment of mantle cell lymphoma.
Deshpande A; Wang Y; Munoz J; Jain P
Drugs Today (Barc); 2022 Jun; 58(6):283-298. PubMed ID: 35670706
[TBL] [Abstract][Full Text] [Related]
12. Risk factors and outcome of Chimeric Antigen Receptor T-Cell patients admitted to Pediatric Intensive Care Unit: CART-PICU study.
Caballero-Bellón M; Alonso-Saladrigues A; Bobillo-Perez S; Faura A; Arqués L; Rivera C; Català A; Dapena JL; Rives S; Jordan I
Front Immunol; 2023; 14():1219289. PubMed ID: 37600775
[TBL] [Abstract][Full Text] [Related]
13. Taming the beast: CRS and ICANS after CAR T-cell therapy for ALL.
Sheth VS; Gauthier J
Bone Marrow Transplant; 2021 Mar; 56(3):552-566. PubMed ID: 33230186
[TBL] [Abstract][Full Text] [Related]
14. EASIX and Severe Endothelial Complications After CD19-Directed CAR-T Cell Therapy-A Cohort Study.
Korell F; Penack O; Mattie M; Schreck N; Benner A; Krzykalla J; Wang Z; Schmitt M; Bullinger L; Müller-Tidow C; Dreger P; Luft T
Front Immunol; 2022; 13():877477. PubMed ID: 35464403
[TBL] [Abstract][Full Text] [Related]
15. Immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor T-cell therapy for lymphoma: predictive biomarkers and clinical outcomes.
Holtzman NG; Xie H; Bentzen S; Kesari V; Bukhari A; El Chaer F; Lutfi F; Siglin J; Hutnick E; Gahres N; Ruehle K; Ahmad H; Shanholtz C; Kocoglu MH; Badros AZ; Yared JA; Hardy NM; Rapoport AP; Dahiya S
Neuro Oncol; 2021 Jan; 23(1):112-121. PubMed ID: 32750704
[TBL] [Abstract][Full Text] [Related]
16. Anakinra for Refractory Cytokine Release Syndrome or Immune Effector Cell-Associated Neurotoxicity Syndrome after Chimeric Antigen Receptor T Cell Therapy.
Gazeau N; Liang EC; Wu QV; Voutsinas JM; Barba P; Iacoboni G; Kwon M; Ortega JLR; López-Corral L; Hernani R; Ortiz-Maldonado V; Martínez-Cibrian N; Martinez AP; Maziarz RT; Williamson S; Nemecek ER; Shadman M; Cowan AJ; Green DJ; Kimble E; Hirayama AV; Maloney DG; Turtle CJ; Gauthier J
Transplant Cell Ther; 2023 Jul; 29(7):430-437. PubMed ID: 37031746
[TBL] [Abstract][Full Text] [Related]
17. Clinical and radiologic correlates of neurotoxicity after axicabtagene ciloleucel in large B-cell lymphoma.
Strati P; Nastoupil LJ; Westin J; Fayad LE; Ahmed S; Fowler NH; Hagemeister FB; Lee HJ; Iyer SP; Nair R; Parmar S; Rodriguez MA; Samaniego F; Steiner RE; Wang M; Pinnix CC; Adkins S; Claussen CM; Martinez CS; Hawkins MC; Johnson NA; Singh P; Mistry HE; Horowitz S; George S; Feng L; Kebriaei P; Shpall EJ; Neelapu SS; Tummala S; Chi TL
Blood Adv; 2020 Aug; 4(16):3943-3951. PubMed ID: 32822484
[TBL] [Abstract][Full Text] [Related]
18. Toxicity and efficacy of CAR T-cell therapy in primary and secondary CNS lymphoma: a meta-analysis of 128 patients.
Cook MR; Dorris CS; Makambi KH; Luo Y; Munshi PN; Donato M; Rowley S; Saad A; Goy A; Dunleavy K; Ali A
Blood Adv; 2023 Jan; 7(1):32-39. PubMed ID: 36260735
[TBL] [Abstract][Full Text] [Related]
19. Frontal Intermittent Rhythmic Delta Activity Is a Useful Diagnostic Tool of Neurotoxicity After CAR T-Cell Infusion.
Huby S; Gelisse P; Tudesq JJ; Labauge P; Duflos C; Cartron G; Gallerand MA; Platon L; Badiou S; Lamure S; Menjot de Champfleur N; Ayrignac X; Taieb G
Neurol Neuroimmunol Neuroinflamm; 2023 Jul; 10(4):. PubMed ID: 37059470
[TBL] [Abstract][Full Text] [Related]
20. Outcomes of patients with secondary central nervous system lymphoma following CAR T-cell therapy: a multicenter cohort study.
Epperla N; Feng L; Shah NN; Fitzgerald L; Shah H; Stephens DM; Lee CJ; Ollila T; Shouse G; Danilov AV; David KA; Torka P; Hashmi H; Hess B; Barta SK; Romancik JT; Cohen JB; Annunzio K; Kittai AS; Reneau J; Zurko J; Nizamuddin IA; Winter JN; Gordon LI; Ma S; Patel R; Nastoupil L; Ahmed S; Karmali R
J Hematol Oncol; 2023 Nov; 16(1):111. PubMed ID: 37946255
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]